Trillium therapeutics
WebContact Email [email protected]. Phone Number 416-595-0627. Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. … WebMar 1, 2024 · Trillium Therapeutics Inc. is a clinical stage immuno-oncology company. The Company develops therapies for the treatment of cancer and has preclinical programs, …
Trillium therapeutics
Did you know?
WebAug 23, 2024 · Pfizer has strengthened its oncology pipeline with a deal to acquire the clinical stage immuno-oncology company Trillium Therapeutics for $2.26 billion. Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells. Its two lead molecules, TTI ... WebDec 9, 2024 · Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has ...
WebJun 9, 2024 · About Trillium Therapeutics Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, ... WebAug 31, 2024 · On 23 August, Pfizer stated its aim to acquire Trillium Therapeutics, a Canadian immuno-oncology company focused on developing drugs for several blood cancers, in a $2.26bn deal. Through this proposed acquisition, Pfizer aims to solidify its place in the blood cancer treatment space after the company generated $10.9bn in …
WebPfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash. The companies have signed a definitive agreement for the deal in August this year. Trillium Therapeutics develops new therapies for cancer. WebMay 16, 2024 · Trillium is expanding TTI-621/622 from monotherapy to combinations in a wide variety of cancers (Fig. 3). Fig 3: Future clinical trials in combination with other therapeutics. Adapted from here .
WebMar 18, 2024 · Trillium Therapeutics Inc (Trillium), formerly Neurogenesis Biotech Corp, a subsidiary of Pfizer Inc, is a clinical-stage immuno-oncology company, which develops novel therapies for the treatment of cancer. The company uses biologic and small molecule-based approaches to develop its portfolio. Its lead program, TTI-621 (intravenous), a SIRPαFc ...
WebJun 30, 2024 · About Trillium Therapeutics. Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, ... theodore of tarsus archbishop of canterburyWebApr 7, 2024 · Trillium Therapeutics Inc is a Canada-based company that develops therapies for the treatment of cancer. The countries covered in the HER2 inhibitors market report are Australia, ... theodore oldsWebApr 28, 2024 · CAMBRIDGE, Mass., April 28, 2024 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of ... theodore orrWebMay 31, 2024 · About Trillium Therapeutics. Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. … theodore orleanskiWebAug 23, 2024 · Pfizer has agreed to acquire Trillium Therapeutics for $2.26 billion, the companies said today, in a deal designed to bolster the buyer’s oncology drug portfolio by adding Trillium’s two lead ... theodore osbornWebJun 30, 2024 · About Trillium Therapeutics. Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target ... theodore ongaroWebAug 24, 2024 · Pfizer has signed a definitive agreement to acquire all the outstanding shares of clinical-stage immuno-oncology company Trillium Therapeutics for a proposed equity value of $2.26bn, or $18.50 per share, in cash.. Trillium focuses on developing advanced treatments for cancer and its portfolio comprises biologics that can boost the ability of … theodore of mopsuestia theology